Quark Pharma withdraws its long-shot IPO
Quark Pharmaceuticals, the biotech chameleon that tried to portray itself as a hot new RNAi company, has withdrawn its IPO. The company said that “the terms currently obtainable in the public marketplace are not sufficiently attractive” to continue with the offering. Quark had hoped to raise as much as $81 million in the offering.
It’s clearly a tough IPO market out there for biotechs, but investors may have been well served by Quark’s decision to take a pass at the public markets for now.
Next Story: Quark Pharma IPO collapses
Previous Story: LS9 says it has produced petroleum-like cleaner fuel
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.